0001628280-26-033633
SEC filingRevenue grew 1.1% YoY, gross margin expanded to 35.9% as cost cuts offset divestiture headwinds.
For Q1 2026, 3D Systems reported revenue of $95.5M, a 1.1% increase from $94.5M in Q1 2025. The growth was driven by higher product revenue (+$3.0M) from increased materials and printer volumes in the dental and aerospace & defense markets, partially offset by lower service revenue (-$2.0M) due to divestitures. Gross profit rose 5.1% to $34.3M, and gross margin expanded 130 basis points to 35.9%, primarily due to favorable volume mix, especially higher materials sales. Cost management was a standout: SG&A decreased 37.0% to $31.3M and R&D declined 51.0% to $9.6M, reflecting headcount reductions, lower incentive compensation, and reduced outside services. Consequently, operating loss narrowed significantly from -$36.8M to -$6.6M.
Non-operating income of $4.6M (vs. $1.4M) included a $2.6M gain from dilution of an equity method investment, higher foreign exchange gains, and increased interest expense from the 2030 Notes. The effective tax rate was -72.2% due to a full valuation allowance on deferred tax assets.
Healthcare Solutions revenue grew 21.3% to $50.1M, driven by strong materials volume (especially a key dental customer), parts manufacturing, and printer sales. Segment gross profit rose 39.1% to $22.3M, yielding a gross margin of 44.5% (vs. 38.8% prior year). Industrial Solutions revenue fell 14.7% to $45.4M, dragged by divestitures and lower jewelry market volumes, though aerospace & defense sales increased. Segment gross profit declined 27.7% to $12.0M, with margin compressing from 31.3% to 26.5% due to unfavorable mix and divestiture impact.
Management emphasized ongoing cost discipline under the 2025 Restructuring Plan, with no significant additional charges expected. The company highlighted its focus on sustainable growth and profitability through streamlined operations and continued R&D investment. Divestitures (Geomagic, 3DXpert/Oqton) have reshaped the portfolio, reducing revenue but improving cost structure. Liquidity remains adequate with $85.1M cash, though the company faces upcoming debt maturities (2026 Notes due November 2026). No formal guidance was provided, but the trajectory suggests continued margin improvement if volume trends persist.
As of March 31, 2026, the company held $85.1M in cash and cash equivalents, down from $95.6M at December 31, 2025. Total assets were $513.1M, with current assets of $340.7M. Inventories remained stable at $127.3M. Total debt (carrying value) was $90.7M, consisting of $3.9M in 0% convertible notes due 2026 and $86.8M in 5.875% convertible senior secured notes due 2030. Shareholders' equity was $234.3M, down from $240.4M due to net loss and foreign currency translation losses. The company had $86.5M in total cash, cash equivalents, and restricted cash.
Purchase commitments totaled $20.4M as of March 31, 2026, primarily related to printer assemblies, inventory, capital expenditures, and software licenses. Of this, $8.0M is expected to be due within the next twelve months. The company also has a $0.4M standby letter of credit as security for a long-term real estate lease, with a maturity date of June 2026. The company has a $1.5M short-term liability for remaining milestone payments related to the redeemable non-controlling interest. The Volumetric earnout dispute has a $1.8M settlement offer recorded in accrued liabilities.
Capital expenditures were $2.1M for the three months ended March 31, 2026, representing 2.2% of sales. No share buybacks or dividends were disclosed. The company made a $0.5M payment for the purchase of non-controlling interest. Debt issuance cost amortization was $0.5M. The company is in compliance with all financial covenants related to its long-term debt.
Revenue by segment: Healthcare Solutions $50.1M (up 21.3% YoY), Industrial Solutions $45.4M (down 14.7% YoY). Gross profit: Healthcare $22.3M (44.5% margin), Industrial $12.0M (26.5% margin). Depreciation and amortization within gross profit: Healthcare $1.4M, Industrial $0.6M. Revenue by geography: Americas $57.1M (including US $56.8M), EMEA $34.3M (including Germany $15.8M), APAC $4.1M. Two customers in Healthcare Solutions accounted for 17.4% and 10.0% of consolidated revenue.